On August 7, 2023, Formycon AG and Fresenius Kabi announced that they have reached a settlement with Johnson & Johnson (“J&J”) in the United States relating to FYB202, a proposed ustekinumab biosimilar to STELARA®, marketed...more
8/17/2023
/ Amgen ,
Biosimilars ,
Fresenius ,
Janssen Pharmaceuticals ,
Johnson & Johnson ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Samsung Bioepis ,
Teva Pharmaceuticals